3[2]Snyder RD, Friedman MB. Enhancement of cytotoxicity and clastogenicity of L-DOPA and dopamine by manganese and copper. Mutation Research, 1998,405(1) :1～8
4[3]Emilien, G Maloteaux, JM Geutts et al. Dopamine receptorsphysiologicalunderstanding to therapeutic potential intention.Pharmacology＆therapeutics,1999,84(2):133～156
5[9]StaCy M. parkinson's dlsease:therapeutiC ChoiCes and timlng deCidions inpatientmanagement (interViewbyWayneKuznar). Geriatrics, 1999, 54(10):44～49
6[10]Patpbillip S. Seveml classes of New Drugs Emerging For Parkinson Disease. 美国医学会杂志 ,2000,19(2) :98～101
7[12]ShiOZdki, s IChikawa, s Nakamura, et, al. Actions of adenoslne A2A reCeptorantagonist KW - 60020 on drug - induced Catalepsy and hypokinesia caused by reserpine or mptp. Psychophannacology, 1999,147(1):90～95
8[14]Ceravolo, R salvemi, s Piccini, et, al. Acute and chronic effeCts of Clozapine in essential tremor. Movement disorders, 1999,14(3) :468～472
9[15]Roghanl, M Behzadi, et, al. Neuroprotectivee effect of vitamin E on the early model fo Parhnson's disease in ratzbehavioral and histochemical evidence. Brain Research,2001,892(1) :211～217
10[16]Rednitzky, Rl. Can calcium antagonists provide a neuroprotective effect in parkinson's dicease? [J] .Drugs. 1999,57(6) :845～849
